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The aim of this study was to investigate retinal and peripheral microvascular function in asymptomatic 
individuals that fall into different BP groups when using either the ESC/ESH or the ACC/AHA 
guidelines. Retinal and peripheral microvascular function was assessed in 358 participants by means 
of dynamic retinal vessel analysis and digital thermal monitoring, respectively. Blood pressure 
and lipid panel were also evaluated. Retinal vascular function measured in all groups belonging to 
the ACC/ASH classifications were within the normal values for age‑matched normal population. 
Individuals classed as grade 1 hypertension according to the ESC/ESH guidelines, however, exhibited 
a significantly decreased artery baseline (p = 0.0004) and MC (p = 0.040), higher  slopeAD (p = 0.0018) 
and decreased vein MC (p = 0.0446) compared to age matched normal individuals. In addition, they 
also had significant lower artery baseline, artery BDF, MD and MC than individuals classed as stage 
1 hypertension based on the ACC/ASH guidelines (p = 0.00022, p = 0.0179, p = 0.0409 and p = 0.0329 
respectively). Peripheral vascular reactivity (aTR) was lower in ESC /ESH grade I compared to those 
graded ACC/ASH stage I hypertension (p = 0.0122). The conclusion of this study is that microvascular 
dysfunctions is present at multiple levels only in individuals with ESC/ESH grade 1 hypertension. This 
observation could be important when deciding personalised care in individuals with early hypertensive 
changes.
One of the main differences between the latest guidelines published in 2018 by the European Society of Cardiol-
ogy/European Society of Hypertension (ESC/ESH) and those published in 2017 by The American College of 
Cardiology/American Heart Association (ACC/AHA) is the cut-off for what is considered elevated blood pres-
sure (BP) and the first stage of hypertension (HTN)  diagnosis1. As it can be expected, such difference is bound 
to have a high impact on clinical diagnosis and management of HTN. By using the ACC/AHA guidelines, the 
number of patients diagnosed with having this disease increased significantly and so did the pressure on the 
health system and economy. In addition, such change in practice has also a significant impact on the patients’ 
physical and psychological  wellbeing1. Nevertheless, it would seem sensible that, in individuals with higher risk 
for cardiovascular disease (CVD), early diagnosis and interventions are applied at lower BP values. Indeed, both 
ECC/ESH guidelines and ACC/AHA have recognised this fact and recommended considering treating patients 
with high CVD risk at a BP threshold lower than their current cut-off for grade/stage 1  HTN2. In this way, 
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positive progress is made towards considering individual over population factors when considering someone 
of being at risk for CVD.
But what is the real measure of a high CVD risk? Today, the gold standard for absolute CVD risk is based 
on the Framingham 10-year CVD risk score (FRS)3. Other risk scores, such as the Prospective Cardiovascular 
Mὒnster (PROCAM) and the European Society of Cardiology Systematic Coronary Risk Evaluation (SCORE)4,5 
are also being used for the same purpose. These calculations are based, however, only on few non-modifiable as 
well as some modifiable risk factors, thus limiting their ability to accurately predict the risk for CVD in all indi-
viduals. Indeed, it has been shown that they could either over‐ or underestimate actual risk for CVD in a large 
number  cases4,6,7. Consequently, it has been suggested that other factors, such as obesity, psychosocial stress and 
lifestyle, to name just a few, should also be included for more precise  estimations8. In addition, vascular endothe-
lial function, a parameter often overlooked, is essential not only for investigations into the pathophysiology of 
CVD but also for better CVD risk  stratification9–11. Assessing vascular endothelial function is usually performed 
using techniques such as ultrasound flow‐mediated dilation (FMD), pulse wave analysis (PWA), plethysmog-
raphy and  iontophoresis12. These tests can, however, be complex and time‐consuming, and are performed only 
in highly specialized services, this contributing to the lack of inclusion of this parameter in the more largely 
circulated risk scores. Nevertheless, parameters such as retinal microvascular function has been found to show 
a good association not only with various circulatory markers for  CVD13,14, but also with other modifiable and 
non-modifiable risk factors for this disease such as  obesity15, family  history16 and  age17,18. Retinal microvascular 
function assessments provide instant integrated and dynamic data analysis that is specific to each individual. In 
addition, it also correlates with peripheral markers for endothelial dysfunction. Indeed, we have recently shown 
that signs of abnormal vascular function are similarly present and detectable in various microvascular beds, 
despite existing differences in their anatomical and physiological  properties19. This observation is important and 
helps clinician to detect signs of microvascular dysfunction regardless of the method they can access to. By having 
a choice, practitioners can make better decisions whether to treat or not selected patients with lower BP values 
but with additional CVD risk, thus making decisions based on individual, rather that population risk factors, 
an important step towards personalised management of HTN. Nevertheless, in individuals without higher risk, 
the decision to treat might not be always justified. In order to shed a possible light on the validity of lowering 
the cut-off for the diagnosis of early hypertension in individuals without additional CVD risk, this study aimed 
to analyse the retinal and peripheral microvascular function in subjects that fall into different BP groups when 
using either the ESC/ESH or the ACC/AHA  guidelines2,20.
Methods
Study participants. Healthy individuals over the age of 30 were recruited through advertisements at the 
Vascular Research Laboratory, Aston University (Birmingham, UK). Ethical approval was sought from the rel-
evant local ethics committee (Aston University’s Ethics Committee), and written informed consent was received 
from all participants prior to study enrolment. The study was designed and conducted in accordance with the 
tenets of the Declaration of Helsinki, and all study‐related procedures adhered to institutional  guidelines14,17.
Study exclusion criteria were defined as the positive diagnosis of hypertension, CVD, cerebrovascular disease, 
peripheral vascular disease, dyslipidaemia, diabetes, as well as other metabolic disorders or chronic diseases that 
required treatment. Individuals using any vasoactive medications were also excluded from the study. Potential 
participants were also screened for ocular diseases and were excluded from the study if they had a refractive 
error of more than ± 3DS and more than ± 1DC equivalent, intra‐ocular pressure (IOP) greater than 21 mmHg, 
cataract or any other media opacities, as well as history of intra‐ocular surgery or any form of retinal or neuro‐
ophthalmic disease affecting the ocular vascular  system14,18.
General investigations. Participants who met the inclusion criteria were invited to a 2-h visit. Initially, 
they were requested to complete a general health history questionnaire, also detailing daily diet, physical activity 
and alcohol consumption. All study‐related measurements were performed between 8 and 11 am following a 
12‐hr overnight fast, which included refraining from alcohol and caffeine.
Standard anthropometric measures of height and weight were recorded to determine body mass index 
(BMI = weight/height2)14.
Blood pressure assessment and patients grouping. Measurements of BP were performed on two 
separate occasions, one in-clinic and one out-of-clinic2,20. During the in-clinic visit, BP was measured in a quiet 
environment, with the patient seated for 5 min, 3 times at 1–2 min intervals using an automatic BP monitor 
(UA‐767; A & D Instruments Ltd, UK) and an adequate cuff size. The BP values were confirmed by a sec-
ond measurement using a computer‐operated ambulatory BP and electrocardiogram (ECG) monitor (Cardi-
otens‐01, Meditech Ltd, Budapest, Hungary). All subjects maintained their normal activity and were carefully 
instructed to complete a diary each time their activities changed, or when any chronic medication was taken. The 
24‐h BP were later downloaded and analysed using the ‘Medibase’ software program (Meditech). SBP as well as 
diastolic DBP measurements were calculated for the day-time (6 am to 10 pm) and night-time (10 pm to 6 am) 
intervals. At least 80% of the programmed recordings were required for a diurnal curve to be considered in the 
present  analysis14,19.
Using the day-time SBP and DBP values, study participants were stratified into three subcategories: “normal”, 
“high normal” and ‘’Grade I’’ as recommended by the 2018 ESC/ESH Guidelines. They were then also further 
classified into three other subcategories: “normal”, “elevated” and “stage I” as recommended by the 2017 ACC/
AHA guidelines. Subjects classed as “optimal” according to the 2018 ESC/ESH guidelines were excluded and 
their values were included in our pool of “normal”  data14.
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Dynamic retinal vessel analysis. Retinal vessel reactivity was assessed using the dynamic retinal ves-
sel analyser (DVA, IMEDOS GmbH, Jena, Germany) in accordance with an established  protocol21. All meas-
urements were performed in a temperature-controlled environment (22 °C) following pupil dilation with 1% 
Tropicamide (Chauvin Pharmaceuticals Ltd, UK) and were taken from the inferior temporal vessel branches 
approximately one and a half disc diameters from the optic nerve head of one unselected eye. Using a validated 
in-house algorithm, the following vessel reactivity and time-course parameters were determined for each flicker 
cycle and then averaged over the 3 cycles, with the artery and vein regarded separately as follows: the average 
baseline diameter and range of maximum and minimum baseline vessel diameters (baseline diameter fluctua-
tion, BDF); the maximum vessel dilation diameter during flicker stimulation expressed as a percentage change 
relative to baseline diameter (MD%) and the time taken in seconds to reach the maximum diameter (tMD); the 
maximum vessel constriction diameter during the postflicker recovery period expressed as a percentage change 
relative to baseline diameter (MC%) and the time taken in seconds to reach the maximum vessel constriction 
diameter (tMC); the overall dilation amplitude (DA) calculated as the difference between MD and MC; and the 
baseline-corrected flicker response (BCFR) used to describe the overall dilation amplitude after normalizing 
for fluctuations in baseline diameters (DA-BDF). In addition, the arterial (A) and venous (V) dilation slopes 
 (SlopeAD/VD = (MD − baseline diameter) / tMD) and constriction slopes  (SlopeAC/VC = (MC − MD) / tMC) were 
also calculated (Fig. 1)16. The sensitivity and reproducibility of DVA assessments in healthy subjects has been 
reported previously and the normal expected retinal responses to flicker-light stimulation have been reported to 
be around 6.9 ± 2.8% in arteries and 6.5 ± 2.8% in  veins22,23.
Digital thermal monitoring (DTM). The peripheral microvascular reactivity at the level of the fingertips 
was assessed using VENDYS 5000 BCE DTM system (Endothelix, Inc, Houston, TX, USA) according to an 
established  protocol24. Figure 2 shows a representative example of a temperature–time trace and the primary 
DTM-derived measures, related to thermal debt and recovery that were recorded and calculated.
Temperature rebound (TR): maximum temperature − start temperature (just before cuff inflation); adjusted 
temperature rebound (aTR): temperature rebound/start temperature;  area under the curve temperature 
rebound (AUCTR): area under the curve between maximum temperature and minimum temperature. The 
post-occlusive adjusted temperature rebound aTR determined by the software algorithm is directly associated 
with the extent of the subjects vascular  reactivity25. An aTR below 1 is considered poor cardiovascular reactivity, 
whereas an aTR between 1 and 2 is considered intermediate vascular reactivity and an aTR of > 2 is considered 
healthy vascular reactivity.
Figure 1.  Graphical presentation of the dynamic vessel response profile displaying the parameters calculated 
and used in analysis. (DA) calculated as (MD-MC). (MD%) calculated as the percent increase from baseline to 
MD. (MC%) calculated as the percent constriction below baseline following MD.
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Statistical analysis. All data are reported as mean (SD) unless otherwise indicated. The Shapiro–Wilk 
test was used to determine the distribution of the data. Univariate associations were determined using Pear-
son’s (normally distributed data) or Spearman’s method (non‐normally distributed data), and forward stepwise 
regression analyses were performed to test the influences of systemic and circulating markers on the measured 
variables. Differences between groups were subsequently assessed using one‐way analysis of variance (anova) 
or analysis of covariance (ancova). p values of < 0.05 were considered significant. All analyses were performed 
using Statistica software.
Results
A total number of 372 participants were initially screened for study inclusion of which 14 individuals were 
excluded based on the quality of retinal vascular image analysis or to the fact that they did not tolerate the 
ambulatory BP measurements. The remaining 358 participants were included in the final analysis and classified 
into 3 study groups using the current ESC/ESH Guidelines (normal BP:66 individuals,; high normal BP: 40 indi-
viduals; and grade 1 hypertension: 53 individuals). A further three groups were decided based on the ACC/AHA 
guidelines: (normal BP: 83 individuals; Elevated BP: 46 individuals; and stage 1 hypertension: 70 individuals).
General characteristics of the study population are presented in Table 1. There were no significant differences 
in age, gender, BMI, HR, IOP, glucose, TG, cholesterol, LDL-c, HDL-c and body composition between all the 
study groups (all p > 0.05). There was a significant difference between groups in SBP and DBP (p < 0.001). In 
addition, there was also significant differences between the peripheral vascular reactivity (aTR) between ESC /
ESH grade I compared to ACC/ASH stage I hypertension, with individuals graded as ESC /ESH grade I having 
lower aTR than those graded ACC/ASH stage I hypertension (p = 0.0122).
Comparisons of group differences in measured retinal arterial and venous DVA parameters after flicker 
stimulation are presented in Tables 2 and 3. All values reported are based on data averaged across the three flicker 
cycles with arteries and veins considered separately. Values were further compared to the average normal values 
for the groups’ corresponding age range.
Retinal vascular response. After controlling all the influential covariates identified in multivariate analy-
sis, there were no statistically significant differences in baseline diameter, BDF, BCFR, tMD and tMC,  slopeAD 
and  slopeAC between the ACC/AHA and ESC/ESH normal BP groups (p > 0.05, Table 2). Similarly, there were no 
significant group differences found between ACC/AHA elevated and ESC/ESH high normal BP groups (p > 0.05, 
Table 2). However, individuals classed as grade 1 hypertension according to the ESC/ESH guidelines had sig-
nificant lower artery baseline, artery BDF, MD and MC than individuals classed as stage 1 hypertension based 
on the ACC/ASH guidelines (p = 0.0002, p = 0.0179, p = 0.0409 and p = 0.0329 respectively). In addition, while 
the retinal vascular reactivity parameters measured in individuals classed as stage 1 hypertension according to 
ACC/ASH guidelines were still within the normal limits for their age, the ESC/ESH grade I hypertensive group 
exhibited a significantly decreased artery baseline (p = 0.0004) and MC (p = 0.040) as well as higher  slopeAD 
(p = 0.0018) compared to age matched population average (Table 2; Fig. 3). Similarly, vein MC was significantly 
decreased in ESC /ESH grade I compared to ACC/ASH stage I hypertension (p = 0.0383). In addition, vein MC 
was significantly decreased only in the ESC/ESH grade I hypertension compared to age matched population 
average (p = 0.0446) (Table 3; Fig. 3).
Figure 2 .  Graphical representation of the Digital Thermal Monitor software analysis. T MAX, maximum 
temperature; TMIN, minimum temperature; AUCTR, Area under the curve temperature.
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Table 1.  General characteristics of the study population. Abbreviations: SBP: systolic blood pressure; DBP: 
diastolic blood pressure; HR: heart rate; IOP: intraocular pressure; BMI: body mass index; TG: triglycerides; 
T. Chol: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein; aTR: 
adjusted temperature rebound *Significant p values are indicated where p < 0.05 was considered significant.
ACC/AHA 
Normal












ACC/AHA Stage I 
SBP:130–139
DBP:80–89
ESC/ESH Grade I 
SBP:140–159
DBP:90–99 p value
Number 83 66 – 46 40 – 70 53 –
Gender 30 M:53F 34 M:32F – 29 M:17F 22:18F – 44 M:37F 32 M:21F –
Age (years) 40.1.8 (1.35) 43.91 (1.70) 0.0859 42.83 (2.31) 45.80 (2.53) 0.3897 44.88 (3.4) 48.77 (2.7) 0.1063
SBP(mmHg) 109.43 7.08) 122.52 (4.98) 0.0000* 124.17 (6.88) 131.03 (6.74) 0.0002* 134.61 (8.72) 142.00 (7.52) 0.0000*
DBP(mmHg) 68.33 (6.15) 76.15 (5.92) 0.0000* 72.76 (4.98) 83.93 (5.37) 0.0000* 83.95 (4.71) 89.47 (6.54) 0.0000*
HR (bpm) 68.055 (9.28) 65.06 (10.15) 0.0659 63.31 (9.38) 67.37 (10.85) 0.1085 68.37 (10.87) 69.59 (10.93) 0.5467
IOP 13.30 (2.34) 13.41 (2.64) 0.8139 13.25 (2.59) 13.43 (2.25) 0.7123 14.33 (2.63) 15.29 (3.01) 0.0970
BMI (kg/m2) 24.69 (0.36) 25.66 (0.45) 0.0934 26.73 (0.71) 25.70 (0.78) 0.3175 26.49 (4.20) 28.09 (4.40) 0.0680
Body fat % 28.00 (1.68) 23.76 (1.76) 0.0864 23.02 (1.90) 28.31 (2.06) 0.0670 27.65 (2.43) 31.93 (3.97) 0.3651
Body water % 52.51 (1.65) 51.56 (1.73) 0.6907 54.25 (2.30) 48.84 (2.48) 0.1180 46.80 (2.96) 49.44 (4.84) 0.6445
Muscle mass % 47.45 (2.59) 50.89 (2.72) 0.1673 60.94 (3.13) 55.68 (3.38) 0.2599 52.75 (4.29) 43.30 (6.10) 0.2583
Glucose (mmol/L) 4.87 (0.55) 4.93 (0.86) 0.6178 5.07 (0.82) 5.03 (0.60) 0.8433 4.93 (0.92) 5.15 (1.31) 0.3356
TG (mmol/L) 1.139 (0.56) 1.19 (0.61) 0.6345 1.15 (0.48) 1.25 (0.46) 0.4397 1.263 (0.62) 1.44 (0.80) 0.2210
T.Chol (mmol/L) 4.40 (0.78) 4.70 (1.02) 0.5642 4.88 (1.07) 4.55 (0.91) 0.2040 4.50 (0.89) 4.72 (0.86) 0.2516
HDL-C (mmol/L) 1.33 (0.41) 1.37 (0.39) 0.5212 1.35 (0.38) 1.23 (0.58) 0.3288 1.33 (0.56) 1.21 (0.44) 0.2848
LDL-C (mmol/L) 2.57 (0.91) 2.78 (0.12) 0.1639 2.10 (1.09) 2.82 (1.05) 0.5199 2.59 (0.94) 2.90 (0.93) 0.1131
TG/HDL 1.00 (0.81) 1.01 (0.81) 0.9561 0.98 (0.63) 1.35 (0.91) 0.0683 1.21 (0.92) 1.36 (0.94) 0.4460
aTR 1.60 (0.13) 1.93 (0.11) 0.0365* 1.70 (0.11) 1.63 (0.11) 0.7790 1.80 (0.12) 1.20 (0.20) 0.0122*
Table 2.  Summary of retinal arterial vascular function parameters. Abbreviations: ANOVA, analysis of 
variance; ANCOVA, analysis of covariance; Baseline, baseline diameter; BDF, baseline diameter fluctuation; 
BCFR, Baseline corrected flicker response; tMD, time to reach MD; MDp, percent dilation; tMC, time to reach 
MC; MC (%), percent constriction; DA, dilation amplitude (difference between MD and MC during flicker) 
 SlopeAD, slope of arterial dilation;  SlopeAC, slope of arterial constriction. *Significant p values are indicated 



































99.99 (0.002) 99.98 (0.12) 99.88 (0.77) 0.1979 99.83 (0.95) 99.97 (0.92) 0.4346 99.99 (0.62) 97.93 (0.27) 0.0002*
Artery-BDF
5.66 (2.63) 5.64 (2.650) 6.14 (3.46) 0.3461 6.28 (2.87) 5.83 (2.74) 0.5250 5.98 (3.42) 5.02 (2.41) 0.0179*
Artery-MD
103.67 (2.20) 103.57 (2.20) 104.07 (2.24) 0.2000 104.44 (2.2) 104.19 (2.74) 0.5780 104.14 (2.43) 102.75 (4.26) 0.0409*
Artery-tMD
22.14 (10.09) 21.88 (9.63) 20.87 (6.27) 0.5047 20.84 (5.83) 20.27 (6.44) 0.7120 19.86 (6.74) 20.10 (7.11) 0.9493
Artery-MDp
3.67 (2.21) 3.59 (2.20) 4.20 (2.53) 0.1400 4.64 (2.63) 4.48 (2.75) 0.7901 4.15 (2.44) 4.01 (2.55) 0.1020
Artery-MC
97.51 (1.89) 97.73 (0.19) 97.64 (0.25) 0.7691 97.83 (1.82) 97.53 (2.15) 0.5410 97.58 (1.80) 96.08 (4.97) 0.0329*
Artery-tMC
27.05 (8.31) 27.47 (7.36) 27.88 (6.98) 0.7455 28.09 (6.60) 28.05 (6.44) 0.9810 27.49 (6.70) 28.85 (7.96) 0.3641
Artery-MCp
− 2.49 (1.89) − 2.22 (1.84) − 2.056 (1.87) 0.6124 − 1.99 (1.95) − 2.14 (2.14) 0.3810 − 2.41 (1.80) − 1.94 (1.72) 0.2002
Artery-DA
6.16 (2.95) 5.77 (2.87) 6.17 (2.96) 0.5191 6.61 (2.95) 7.30 (3.63) 0.4310 6.57 (3.02) 6.71 (2.91) 0.8096
Artery-BCFR
0.56 (2.73) 0.30 (2.57) 0.26 (2.97) 0.9244 0.43 (2.74) 0.44 (3.02) 0.1681 0.67 (3.07) 0.89 (3.12) 0.7326
Artery-SlopeAD
0.21 (0.13) 0.21 (0.16) 0.25 (0.15) 0.1347 0.27 (0.16) 0.26 (0.32) 0.1902 0.28 (0.20) 0.35 (0.30) 0.2335
Artery-SlopeAC
− 0.36 (0.30) − 0.36 (0.45) − 0.30 (0.22) 0.3600 − 0.31 (0.22) − 0.32 (0.18) 0.9603 − 0.29 (0.20) − 0.27 (0.51) 0.2826
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No significant group differences in any of the other measured arterial DVA parameters were identified (all 
p > 0.05).
Discussion
The present study looked at the peripheral and retinal microvascular function in various BP groups divided 
according to either the ESC/ESH or the ACC/AHA guidelines. Our report shows, for the first time, that independ-
ent of all systemic influences, retinal microvascular dysfunction firstly manifest itself only in individuals classed 
as ESC/ESH grade 1 hypertension. In contrast, subjects classed as ACC/AHA stage 1 hypertension exhibited 
normal retinal microvascular behaviour after provocation using flickering light. In addition, ESC/ESH grade 
1 hypertension individuals also exhibited lower peripheral vascular reactivity than those graded as ACC/AHA 
stage 1 hypertension.
It is well known that microvascular dysfunction is a parameter highly predictive of cardiovascular  events26. 
Due to this quality, its early identification is extremely important, especially in individuals at risk for CVD, 
including those with borderline BP values or classed as grade/stage 1 hypertension. Indeed, similar to what is 
known for so long in the literature about the effects of systemic hypertension on  microvasculature27 in the present 
study we have shown that individuals classed as ESC/ESH grade 1 hypertension demonstrated abnormal periph-
eral and retinal microvascular function. Indeed, at the retinal vascular level, both vasodilation and vasoconstric-
tion of the retinal arteries and veins were affected. Nevertheless, as all patients with essential hypertension are 
known to demonstrate microvascular endothelial dysfunction from early  stages28, it is puzzling how individuals 
classed as ACC/AHA stage 1 hypertension failed to show such abnormalities. This is an important observation 
that requires further careful consideration since changes in diagnostic cut-off for systemic hypertension towards 
lower BP values in individuals without additional risk factors has a very high impact not only on the clinical 
practice and economy but also on each individual well-being1.
Beside its direct effect on the vascular functionality, hypertension is also known to cause an acceleration of the 
ageing process of the vascular  function29. We have previously demonstrated that, in ageing, normal individuals 
there is a decline in retinal vasoregulative capacity in both dilatory and constrictory phases that was independ-
ent of any systemic  influences17 and we have linked this abnormal response to the possibility of an age-related 
increase in oxidative  stress19. Nevertheless, the subjects included in the current paper were much younger that 
those included in our ageing studies. It is possible that, the abnormal microvascular function observed in indi-
viduals classed as ESC/ESH grade 1 hypertension was indeed due to a reduced nitric oxide (NO) availability 
through excess inhibition by reactive oxygen species (ROS)30; however, in this case, the main culprit for ROS 
excess was not ageing but, possibly, an increased BP. Indeed, it has been shown that, in hypertensive patients, NO 
Table 3.  Summary of retinal arterial vascular function parameters. Abbreviations ANOVA, analysis of 
variance; ANCOVA, analysis of covariance; Baseline, baseline diameter; BDF, baseline diameter fluctuation; 
BCFR, Baseline corrected flicker response; tMD, time to reach MD; MD (%), percent dilation; tMC, time to 
reach MC; MC (%), percent constriction; DA, dilation amplitude (difference between MD and MC during 
flicker)  SlopeAD, slope of venous dilation;  SlopeVC, slope of venous constriction. *Significant p values are 
indicated where p < 0.05 was considered significant.
Normal Average
ACC Normal

















ACC Stage I 
SBP:130–139
DBP:80–89







99.98 (0.15) 99.96 (0.20) 99.90 (0.78) 0.3996 99.83 (0.97) 99.99 (0.002) 0.3733 99.99 (0.0025) 99.91 (0.0022) 0.4251
Vein-BDF
4.39 (2.04) 4.427 (2.22) 3.94 (2.02) 0.2059 4.09 (2.22) 5.149 (3.48) 0.1583 4.70 (2.74) 4.92 (2.48) 0.7667
Vein-MD
104.34 (2.26) 104.19 (2.16) 104.06 (2.24) 0.7239 104.01 (2.19) 105.31 (2.83) 0.5790 105.10 (2.73) 104.61 (2.245) 0.6224
Vein-tMD
22.55 (6.93) 22.37 (6.90) 21.53 (7.40) 0.5058 22.68 (8.62) 21.25 (6.46) 0.5343 19.82 (5.45) 20.43 (5.81) 0.4213
Vein-MDp
4.36 (2.26) 4.24 (2.15) 4.19 (2.61) 0.9114 4.21 (2.75) 5.310 (2.93) 0.1326 5.10 (2.73) 4.612 (2.24) 0.5127
Vein MC
98.71 (1.27) 98.87 (1.14) 99.20 (1.12) 0.0957 98.36 (1.02) 98.70 (1.51) 0.2408 98.46 (1.123) 97.13 (12.5) 0.0383*
Vein-tMC
31.68 (5.51) 31.23 (5.62) 30.15 (6.38) 0.2990 31.26 (6.61) 30.54 (6.34) 0.6757 30.37 (5.76) 31.0384 (5.20) 0.6642
Vein-MCp
− 1.27 (1.28) − 1.09 (1.18) − 0.70 (1.55) 0.0744 − 0.85 (0.70) − 1.29 (0.81) 0.1973 − 1.17 (1.25) − 1.06925902 0.5289
Vein-DA
5.63 (2.88) 5.325 (2.69) 4.85 (2.81) 0.3302 4.86 (1.69) 6.60 (3.20) 0.0869 6.27 (3.16) 5.6811 (2.60) 0.4637
Vein-BCFR
1.23 (2.19) 0.94 (2.37) 0.98 (2.86) 0.9383 0.66 (2.79) 1.56 (2.84) 0.2202 1.52 (2.49) 0.76220 (1.97) 0.2591
Vein-SlopeAD
0.23 (0.13) 0.23 (0.14) 0.24 (0.16) 0.5595 0.24 (0.175) 0.50 (1.109) 0.1881 0.39 (0.74) 0.2697 (0.13) 0.4007
Vein-SlopeVC
− 0.24 (0.15) − 0.23 (0.14) − 0.20 (0.13) 0.2551 − 0.20 (0.13) − 0.27 (0.16) 0.1062 − 0.25 (0.17) − 0.2318 (0.16) 0.7306
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availability is reduced early in the course of the  disease29. Although we did not measure either the level of NO 
or antioxidative markers in our current cohort of patients, in the light of our previous discovery showing that 
retinal microvascular dysfunction occurs in parallel with changes observed in the level of oxidative stress both 
in  normal19 and individuals with abnormal BP  levels15, it is logic to presume that similar abnormalities occurred 
in our current cohort of individuals with ESC/ESH grade 1 hypertension, thus contributing to the abnormal 
retinal microvascular function measured in these individuals.
Our ESC/ESH grade 1 hypertension also exhibited abnormal retinal venous response to flicker. In previous 
studies, we have already documented that individuals with other categories of cardiovascular risk also exhibit 
abnormal retinal venous responses to flicker-induced  provocation14,16,31,32. Structural retinal venular dilation has 
previously implicated as a strong prediction of adverse CVD  events33,34. Nevertheless, the abnormal functional 
retinal venous responses, as measured by DVA, are still to be confirmed as signs of endothelial dysfunction in 
their own right or as epiphenomena of retinal arterial  dysfunction14,17. In this particular context, our observed 
retinal venular dysfunctionality could reflect a compensatory adaptation following sustained arterial dilation 
during flicker. Further investigation is required to understand the relevance of this kind of response; however, it 
Figure 3.  Comparison of retinal arterial and venous response profile across groups. AU, arbitrary units; 
BDF, baseline diameter fluctuation calculated as the maximum range in vessel diameter during first 30 s of 
baseline readings; MD%, calculated as the percentage change in vessel diameter from baseline to maximum 
following onset of flicker; tMD, time to reach maximum diameter during flicker; tMC, time to reach maximum 
constriction post flicker;  slopeAC &  SlopeVC, calculated as (MC-MD)/(tMC).
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could be hypothesized that a change in venous calibre associated with either structural or endothelial irregulari-
ties could also be used as a marker for cardiovascular risk in individuals with early  hypertension14,16,17.
In addition to a general retinal microvascular dysfunction, our cohort of individuals with ESC/ESH grade 
1 hypertension also exhibited abnormal peripheral microvascular reactivity as assessed by DTM, showing that 
abnormal microvascular function is a general process in these individuals and can be detected al multiple levels 
despite differences in vascular physiology and methodologies.
This study found microvascular dysfunctions to be present at multiple levels only in individuals with ESC/
ESH grade 1 hypertension and not in those classed as stage 1 hypertension according to the latest ACC/AHA 
guidelines. The implications of these observations could be important, especially when clinicians decide their 
intervention based only on controversial, borderline BP values measured in individuals without other CVD risk.
Data availability
The data that support the findings of this study are available on request from the corresponding author.
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